← 返回

E3 泛素连接酶 FBXO38 通过维持 IL15R 信号传导来保持 NK 细胞的抗肿瘤功能

英文原题:The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling.

查看英文原题

The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling.

PubMed 2024/10/01(内容时间) Cancer Immunol Res Q1 · IF 7.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞是主要的固有抗肿瘤效应细胞,但其功能在肿瘤微环境中常受到限制。已有报道表明,E3 连接酶 FBXO38 可加速肿瘤浸润 T 细胞中 PD-1 的降解,从而释放其细胞毒性功能。

在本研究中,我们发现癌症患者和荷瘤小鼠肿瘤内 NK 细胞中 FBXO38 的转录水平显著低于瘤周 NK 细胞。NK 细胞中 FBXO38 的条件性敲除加速了肿瘤生长并增加了肿瘤转移。FBXO38 缺失导致肿瘤浸润 NK(TINK)细胞的增殖和存活受损。在机制上,FBXO38 缺失增强了 TGF-β 信号传导,包括升高 Smad2 和 Smad3 的表达,从而抑制转录因子 Eomes 的表达,并进一步降低 NK 细胞表面 IL15Rβ 和 IL15Rγc 的表达。

因此,FBXO38 缺失导致 TINK 细胞对 IL15 低反应性。与这些观察结果一致,FBXO38 mRNA 表达与多种人类肿瘤中 TINK 细胞的增殖呈正相关。为研究 FBXO38 的治疗潜力,荷人肿瘤小鼠接受了 FBXO38 过表达的人原代 NK 细胞治疗,结果显示肿瘤大小显著减小并延长了生存期。

总之,我们的结果表明,FBXO38 维持 NK 细胞的扩增和存活以促进抗肿瘤免疫,并具有潜在的治疗意义,因为这些结果提示 FBXO38 可被用于增强基于 NK 细胞的癌症免疫治疗。

展开英文摘要原文

Natural killer (NK) cells are the main innate antitumor effector cells but their function is often constrained in the tumor microenvironment. It has been reported that the E3 ligase FBXO38 accelerates PD-1 degradation in tumor-infiltrating T cells to unleash their cytotoxic function.

In this study, we found that the transcriptional levels of FBXO38 in intratumoral NK cells of patients with cancer and tumor-bearing mice were significantly lower than in peritumoral NK cells. Conditional knockout of FBXO38 in NK cells accelerated tumor growth and increased tumor metastasis. FBXO38 deficiency resulted in impaired proliferation and survival of tumor-infiltrating NK (TINK) cells.

Mechanistically, FBXO38 deficiency enhanced TGF-β signaling, including elevating expression of Smad2 and Smad3, which suppressed expression of the transcription factor Eomes and further reduced expression of surface IL15Rβ and IL15Rγc on NK cells. Consequently, FBXO38 deficiency led to TINK cell hyporesponsiveness to IL15.

Consistent with these observations, FBXO38 mRNA expression was positively correlated with the proliferation of TINK cells in multiple human tumors. To study the therapeutic potential of FBXO38, mice bearing human tumors were treated with FBXO38 overexpressed human primary NK cells and showed a significant reduction in tumor size and prolonged survival.

In conclusion, our results suggest that FBXO38 sustains NK-cell expansion and survival to promote antitumor immunity and have potential therapeutic implications as they suggest FBXO38 could be harnessed to enhance NK cell-based cancer immunotherapy.

论文信息

作者
Shi Y、Zheng X、Peng H、Xu C、Sun R、Tian Z、Sun H、Wang X
单位
Key Laboratory of Immune Response and Immunotherapy, The Institute of Immunology, Biomedical Sciences and Health Laboratory of Anhui Province, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.China
文献类型
非美国政府资助研究
期刊
Cancer immunology research2024 Oct 1
原文标识
PubMed 38990095 · DOI 10.1158/2326-6066.CIR-23-1061